Characterizing the Population of a Medical Cannabis Clinic in a Pediatric Hospital

Journal of Palliative Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 3, 2025

Background: Medical cannabis (MC) is increasingly in use due to recent cultural and political changes. Other than patients with Lennox-Gastaut Dravet syndrome, there inadequate literature provide evidence-based support for prescribing MC pediatric patients. Objectives: Characterize the population receiving an recommendation ambulatory palliative care setting quantify patient/family-reported outcomes. Design: Retrospective chart review of electronic medical record (EMR) data. Setting/Subjects: Total n = 46 consecutive advice regarding (n 42) a specialized clinic embedded division 4 inpatient midwestern U.S. hospital between 2019 2022. Measurements: Demographics, diagnosis, symptoms, adverse reactions, patient-reported outcomes, barriers abstracted from EMR. Results: Our sample included mean age 11.7 years (SD 5.4); 50% had neurological diagnosis 25); 37% 14) hematological/oncologic; 13% 6), chronic pain. The most common type recommended was 1:1 Cannabidiol (CBD): tetrahydrocannabinol (THC) tincture. There statistically significant decrease floor days cost. Totally, 35% were able or discontinue other medications. Thematic analysis identified four (product unavailable, difficulty obtaining state card, cost, organizational) subjective symptom improvement. Conclusions: These data characterize at our hospital. Positive outcomes noted across several domains. seems be associated lower health utilization, reduced polypharmacy, increased quality life used without events. In value-conscious environment, warrant further exploration.

Language: Английский

---

Cannabinoids Used for Medical Purposes in Children and Adolescents

JAMA Pediatrics, Journal Year: 2024, Volume and Issue: 178(11), P. 1124 - 1124

Published: Sept. 16, 2024

Importance Cannabinoids are increasingly used for medical purposes in children. Evidence of the safety cannabinoids this context is sparse, creating a need reliable information to close knowledge gap. Objective To study adverse event profile children and adolescents. Data Sources For systematic review meta-analysis, MEDLINE, Embase, PsycINFO, Cochrane Library were searched randomized clinical trials published from database inception March 1, 2024, subject terms keywords focused on cannabis Search results restricted human studies French or English. Study Selection Two reviewers independently performed title, abstract, full-text review, data extraction, quality assessment. Included enrolled at least 1 individual 18 years younger, had natural pharmaceutical cannabinoid as an intervention manage any condition, active comparator placebo. Extraction Synthesis extraction assessment independently. The Preferred Reporting Items Systematic Reviews Meta-analyses (PRISMA) reporting guideline PRISMA-S used. pooled using random-effects model. Main Outcomes Measures primary outcome was incidence withdrawals, withdrawals due events, overall serious events control arms. Secondary outcomes specific based organ system involvement. Results Of 39 175 citations, 23 RCTs with 3612 participants included (635 [17.6%] female 2071 [57.3%] male; not available 2 trials); 11 (47.8%) adolescents only, other 12 (52.2%) children, adolescents, adults. Interventions purified cannabidiol (11 [47.8%]), nabilone (4 [17.4%]), tetrahydrocannabinol (3 [13.0%]), herbal extract dexanabinol (2 [8.7%]). most common indications epilepsy (9 [39.1%]) chemotherapy-induced nausea vomiting (7 [30.4%]). Compared control, associated increased risk (risk ratio [RR], 1.09; 95% CI, 1.02-1.16; I = 54%; trials), (RR, 3.07; 1.73-5.43; 0%; 14 1.81; 1.21-2.71; 59%; trials). Cannabinoid-associated higher RRs diarrhea 1.82; 1.30-2.54; 35%; 10 serum levels aspartate aminotransferase 5.69; 1.74-18.64; 5 trials) alanine 5.67; 2.23-14.39; 6 somnolence 2.28; 1.83-2.85; 8%; Conclusions Relevance In events. findings suggest that long-term studies, including those exploring cannabinoid-related drug interactions tools improve reporting, needed.

Language: Английский

---

Use of Cannabis-Based Medical Products for Pediatric Health Conditions: A Systematic Review of the Recent Literature

Medical Cannabis and Cannabinoids, Journal Year: 2024, Volume and Issue: 7(1), P. 257 - 267

Published: Dec. 10, 2024

Cannabis policy is rapidly changing in the USA and across globe, with 24 states legalizing cannabis for adult use 38 making medical available those qualified conditions. Building on prior evidence, we reviewed recently published literature (from past 5 years) focused treatment effects of naturally derived products within pediatric population.

Language: Английский

---

Expansion of the medical cannabis market in Brazil and regulatory challenges

Cadernos de Saúde Pública, Journal Year: 2024, Volume and Issue: 40(11)

Published: Jan. 1, 2024

Language: Английский

---

A expansão do mercado da cannabis medicinal no Brasil e os desafios da regulação

Cadernos de Saúde Pública, Journal Year: 2024, Volume and Issue: 40(11)

Published: Jan. 1, 2024

---